GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (STU:87S) » Definitions » Inventories, Inventories Adjustments

Roivant Sciences (STU:87S) Inventories, Inventories Adjustments : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Roivant Sciences Inventories, Inventories Adjustments?

Roivant Sciences's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2025 was €0.00 Mil.


Roivant Sciences Inventories, Inventories Adjustments Historical Data

The historical data trend for Roivant Sciences's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Inventories, Inventories Adjustments Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Inventories, Inventories Adjustments
- - - - -

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Roivant Sciences Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Roivant Sciences Business Description

Industry
Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines